Possible scenario
AI Biodefense Validation
42% Chance
Red Queen Bio's work becomes an early proof point that AI-designed countermeasures can keep pace with synthetic or AI-generated pathogen threats. The most likely path is limited but credible government and pharmaceutical validation rather than an immediate mass-market drug launch.
Secondary impacts
- Healthcare +1.1%
- Technology +0.5%
Tickers
- ABCL+2.9%
- ABSI+2.3%
- DNA+1.4%
- REGN+0.5%
Portfolio impact
S&P 500+0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.